Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.2%

80 terminated/withdrawn out of 396 trials

Success Rate

67.7%

-18.8% vs industry average

Late-Stage Pipeline

5%

21 trials in Phase 3/4

Results Transparency

15%

25 of 168 completed trials have results

Key Signals

60 recruiting25 with results42 terminated38 withdrawn

Enrollment Performance

Analytics

Phase 2
123(34.4%)
Phase 1
113(31.6%)
N/A
82(22.9%)
Early Phase 1
19(5.3%)
Phase 3
19(5.3%)
Phase 4
2(0.6%)
358Total
Phase 2(123)
Phase 1(113)
N/A(82)
Early Phase 1(19)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (396)

Showing 20 of 396 trials
NCT06788938Phase 2Recruiting

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

Role: lead

NCT07468916Phase 2Not Yet Recruiting

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Role: lead

NCT04305925Early Phase 1Completed

Focal Laser Ablation of Prostate Cancer

Role: lead

NCT07323641Phase 2Recruiting

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Role: lead

NCT07517211Not Yet Recruiting

A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study

Role: lead

NCT07032701Not ApplicableNot Yet Recruiting

A Disposable Negative Pressure Wound Therapy Device (SNaP) to Promote Wound Healing in the Lower Limbs Following Mohs Micrographic Surgery for Non-melanoma Skin Cancer

Role: lead

NCT04703101Phase 1Recruiting

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

Role: lead

NCT05398302Phase 1Recruiting

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

Role: lead

NCT07468903Not ApplicableNot Yet Recruiting

Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer

Role: lead

NCT06075589Not ApplicableActive Not Recruiting

Psychoeducation for Uveal Melanoma

Role: lead

NCT04119024Phase 1Recruiting

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Role: collaborator

NCT06288113Phase 2Recruiting

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

Role: lead

NCT04624256Not ApplicableActive Not Recruiting

Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial

Role: lead

NCT03996850Active Not Recruiting

SPECT/CT for the Characterization of Renal Masses

Role: lead

NCT04857502Early Phase 1Recruiting

99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

Role: lead

NCT02701153Not ApplicableRecruiting

Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

Role: lead

NCT05115760Not ApplicableActive Not Recruiting

Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy

Role: lead

NCT06216249Phase 2Recruiting

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

Role: lead

NCT04742608Recruiting

Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer

Role: lead

NCT04285671Phase 1Active Not Recruiting

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Role: lead